Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.

Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.

Ascentage Pharma Group Corp. Ltd. has priced the first IPO of the year in the U.S. The offering of 7.32 million shares has the Suzhou, China, and Rockville, Md.-based company looking for gross ...

Ascentage Pharma Hogan.Wan@ascentage.com +86 512 85557777 Stephanie Carrington ICR Healthcare Stephanie.Carrington@icrhealthcare.com (646) 277-1282 Media Relations Sean Leous ICR Healthcare ...

Dajun Yang is co-founder, chairman and CEO of Ascentage Pharma, a Chinese clinical-stage company with a U.S. headquarters in Rockville.

On July 14, Ascentage Pharma Group announced the pricing of an offshore top-up placement. This placement involved 22 million ordinary shares, with a par value of $0.0001 per share, priced at HKD68 ...

Ascentage Pharma Hogan.Wan@ascentage.com +86 512 85557777 Stephanie Carrington ICR Healthcare Stephanie.Carrington@icrhealthcare.com +1 (646) 277-1282 Media Relations: Sean Leous ICR Healthcare ...

JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% YoY, driven by a Takeda payment.

Ascentage Pharma has been listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK since October 2019 and has also been listed on the Nasdaq Global Market ...

Ascentage Pharma Group International (NASDAQ:AAPG) announced the appointments of Veet Misra as the company’s CFO, and Eric Huang, as Senior Vice President of Global Corporate Development and ...

On July 14, Ascentage Pharma Group announced the pricing of an offshore top-up placement. This placement involved 22 million ordinary shares, with a par value of $0.0001 per share, priced at HKD68 ...